Menu
Search
|

Menu

Close
X

OncoSec Medical Inc ONCS.OQ (NASDAQ Stock Exchange Capital Market)

2.50 USD
-0.13 (-4.94%)
As of 12:55 PM EDT
Previous Close 2.63
Open 2.74
Volume 35,948
3m Avg Volume 33,383
Today’s High 2.97
Today’s Low 2.50
52 Week High 19.60
52 Week Low 2.02
Shares Outstanding (mil) 21.17
Market Capitalization (mil) 22.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-3.731
FY18
-10.051
FY17
-10.644
FY16
-16.235
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
--
7.92
Price to Book (MRQ)
vs sector
1.38
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-105.93
14.49
Return on Equity (TTM)
vs sector
-110.71
15.79

EXECUTIVE LEADERSHIP

Avtar Dhillon
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Daniel O'Connor
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Sara Bonstein
Chief Financial Officer, Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Sheela Mohan-Peterson
Chief Legal and Compliance Officer, Since 2015
Salary: $225,966.00
Bonus: --
Sharron Gargosky
Chief Clinical and Regulatory Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

24 N Main St
PENNINGTON   NJ   08534-2218

Phone: +1858.2107333
Site: oncosec.com/

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

SPONSORED STORIES